New Biomarkers Could Revolutionize Early Autism Detection

The Search for Objective Autism Screening Tools

For decades, autism diagnosis has relied on behavioral observations and parental reports—subjective measures that can delay identification until a child is several years old. Now, a wave of new research is exploring biological and digital biomarkers that could make early detection more objective and precise.

A study published in Nature last month identified elevated levels of microbially-derived metabolites in the urine of some autistic children. These chemical signatures may help identify a distinct autism phenotype, potentially enabling targeted screening for this subgroup.

Meanwhile, research in JAMA Network Open demonstrates how eye-tracking biomarkers could be deployed in primary care settings. By measuring how infants visually engage with social stimuli, this approach shows diagnostic promise without requiring specialized clinical expertise.

The Promise of Digital Phenotyping

Beyond biological markers, digital tools are also advancing. AI-powered stool tests—currently in pilot stages with FDA Breakthrough designation—claim over 95% accuracy in detecting autism-associated gut microbiome patterns, though these claims await peer-reviewed validation. Digital phenotyping approaches that analyze behavior patterns through smartphone apps or wearable sensors have also shown potential, as demonstrated in a 2023 Nature study and 2021 Science Advances paper.

Why Earlier Detection Matters

Early autism diagnosis is crucial because it allows for earlier intervention, which research consistently shows leads to better outcomes. Current diagnostic methods often don't identify autism until age 4 or later, missing a critical window of brain plasticity in early childhood. These emerging biomarkers could help close that gap, particularly for children who don't show obvious behavioral signs initially.